Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy

After having constituted the ORTRAI cohort using the CONSORE database at the Jean PERRIN Center, the objective is to characterize the patients both clinically and biologically, histologically and genomically. The clinical and biological characterizations will allow us to confirm that our cohort is comparable with data from the literature. The complement of immunohistochemical and molecular analyses will provide more details on the differences between long-term patients responding to treatment and refractory patients.

Trial Details

NCT ID
NCT07361471
Phase
NA
Sponsor
Centre Jean Perrin
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • molecular analysis
Locations (sample)
  • Clermont-Ferrand, PUY DE DOME, France|45.77969,3.08682

Key Eligibility Criteria

  • Major patient, treated at the Jean Perrin Center, suffering from ovarian cancer at any stage and treated with platinum-based chemotherapy in the fi…
  • Corresponding to one of the two groups below:
  • Refractory group: patients progressing in the first therapeutic line of platinum-based chemotherapy.
  • Group of long-term responders: patients who have not progressed 5 years after the end of first-line platinum salt treatment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →